Intervention not reported
ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3700(3 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2817(2 RCTs)
The intervention showed no clear difference in ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review
Intervention not reported
Dropouts due to adverse event ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3205(3 RCTs)
It is very uncertain whether the intervention changes dropouts due to adverse event ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).
1 finding from 1 review
Intervention not reported
Dropouts due to adverse event ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2670(2 RCTs)
The intervention showed no clear difference in dropouts due to adverse event ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Dropouts due to adverse event ‐ HD‐ICS/LABA vs MD‐ICS LABA№ of participants: 5969(7 RCTs)
The intervention showed no clear difference in dropouts due to adverse event ‐ HD‐ICS/LABA vs MD‐ICS LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3184(3 RCTs)
The intervention probably leads to lower moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2037(2 RCTs)
The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 5452(6 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review